Detecting Recurrent Prostate Cancer With 11C-choline Positron Emission Tomography

Inclusion Criteria

• Patient must have biopsy-proven adenocarcinoma of the prostate initially treated with curative intent (surgery and radiation therapy are most common treatments but other treatments are also eligible).
• Biochemical recurrence defined as any of the following: 1. PSA ? 0.2 ng/mL in at least two sequential tests for patients treated with surgery. 2. PSA ? 0.2 ng/mL above the post therapy nadir for patients treated with radiation therapy, brachytherapy or cryotherapy. 3. PSA ? 0.2 ng/ml above the most recent therapy nadir for patients who have received additional treatment in the recurrent setting
• Patient must have undergone standard-of-care restaging that does not clearly identify site(s) of active disease, or such prior studies must show equivocal findings for which further work-up is considered necessary to make clinical decision. Standard staging examinations may include one or more of the following: CT or MRI, bone imaging (either Tc-99m bisphosphonate scintigraphy MDP or F-18 sodium fluoride PET), or In-111 capromab pendetide scintigraphy no older than 3 months.
• Age ? 18 years.
• Patient must be able to tolerate PET/CT imaging.
• Patient must be able to understand and willing to sign a written informed consent document.

Exclusion Criteria

• Patient must not have claustrophobia that would preclude PET/CT imaging or other contraindications to CT imaging.

Gender

Male

Ages

18 Years and older

Accepts Healthy Volunteers

No